Healios KK (4593) AI Stock Analysis

• Market Cap: ¥65.78B
• Dividend Yield: N/A
• Average Volume (3M): 11.57M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.98
• Revenue Growth: -78.54%
• EPS Growth: 10.23%
• Country: JP
• Employees: 65
• Sector: Healthcare
• Sector Strength: 49
• Industry: Biotechnology
• EPS (TTM): -20.31
• Shares Outstanding: 109,447,500
• 10 Day Avg. Volume: 6,231,319
• 30 Day Avg. Volume: 11,569,699
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥631.33
• Price Target Upside: 5.05% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3

• Rating: 54 Neutral
• Price Target: ¥634.00 ▲(5.49% Upside)

The overall score reflects strong technical momentum, but is heavily weighed down by poor financial performance and unfavorable valuation metrics. The company's positive revenue growth is offset by its struggle with profitability and cash flow management, requiring strategic improvements for sustainable growth.

Healios KK Business Overview & Revenue Model

Company Description

Healios KK (4593) is a pioneering biotechnology company based in Japan, focusing on the development of regenerative medicine and cell therapy products. The company primarily operates in the healthcare sector, leveraging advanced technologies to develop innovative treatments aimed at addressing unmet medical needs. Its core products are based on induced pluripotent stem cells (iPSCs), which have the potential to transform into various cell types, making them highly versatile for therapeutic applications. Healios KK is committed to advancing therapies that can significantly improve patient outcomes in areas such as ophthalmology and immunology.

How the Company Makes Money

Healios KK generates revenue through the development and commercialization of its regenerative medicine and cell therapy products. The company collaborates with research institutions and pharmaceutical companies to advance its product pipeline, which includes therapies targeting retinal diseases and acute respiratory distress syndrome. Key revenue streams include licensing agreements, research and development collaborations, and potential sales of its proprietary cell-based therapies upon regulatory approval. Strategic partnerships and collaborations help the company to share the cost of development and access broader markets, thereby contributing to its earnings.

Healios KK Financial Statement Overview

Summary

Healios KK shows revenue growth potential but struggles with profitability, high leverage, and negative cash flows. The financial performance indicates significant challenges requiring strategic improvements.

Income Statement

Healios KK has shown consistent revenue growth, with a notable increase from ¥27M in 2020 to ¥588M TTM (Trailing-Twelve-Months) in 2025. However, the company struggles with profitability, as evidenced by negative EBIT and net profit margins over the years. The TTM gross profit margin stands at 61.73%, which is strong, yet the negative net profit margin of -743.54% indicates significant challenges in managing operational costs and other expenses.

Balance Sheet

The company's financial leverage is relatively high, with a debt-to-equity ratio of 1.35 TTM. While the equity ratio of 12.46% TTM is low, suggesting limited shareholder funding relative to total assets, the company maintains a solid cash position with negative net debt, indicating more cash and short-term investments than total debt. Return on equity remains negative, reflecting ongoing struggles in generating profits from shareholders' investments.

Cash Flow

Healios KK faces challenges in cash flow management, as indicated by negative operating and free cash flows. The TTM free cash flow of -¥2,278M shows deterioration compared to previous periods. The operating cash flow to net income ratio is negative, reflecting inefficiencies in converting revenue into cash flow. The free cash flow to net income ratio is also negative, underscoring the company's difficulty in generating cash from its operations.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	560.00M	121.00M	90.00M	41.00M	27.00M
Gross Profit	432.00M	108.00M	90.00M	41.00M	27.00M
EBITDA	-2.54B	-2.70B	-4.52B	-3.61B	-3.97B
Net Income	-4.24B	-3.82B	-5.17B	-4.91B	-5.51B
Balance Sheet
Total Assets	14.19B	15.15B	15.03B	23.97B	23.17B
Cash, Cash Equivalents and Short-Term Investments	3.67B	6.72B	7.32B	15.13B	13.92B
Total Debt	2.66B	4.53B	7.15B	11.96B	11.40B
Total Liabilities	12.11B	11.29B	10.65B	15.33B	15.32B
Stockholders Equity	2.06B	3.86B	4.38B	8.64B	7.84B
Cash Flow
Free Cash Flow	-1.83B	-2.85B	-4.86B	-5.39B	-4.26B
Operating Cash Flow	-1.82B	-2.82B	-4.60B	-5.09B	-3.94B
Investing Cash Flow	-1.42B	-1.12B	-909.00M	-736.00M	-1.22B
Financing Cash Flow	77.00M	3.34B	-2.50B	6.99B	803.00M

Healios KK Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 601.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4593, the sentiment is Positive. The current price of 601 is below the 20-day moving average (MA) of 648.00, above the 50-day MA of 542.98, and above the 200-day MA of 330.61, indicating a neutral trend. The MACD of 14.02 indicates Positive momentum. The RSI at 50.90 is Neutral, neither overbought nor oversold. The STOCH value of 30.20 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4593.

Healios KK Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	65 Neutral	¥342.25B	11.52	-0.17%	2.40%	9.60%	-10.22%
7774	58 Neutral	¥21.12B	―		―	6.33%	-250.29%
4593	54 Neutral	¥65.78B	―		―	-78.54%	10.23%
4978	49 Neutral	¥17.63B	206.40		―	13.83%	34.66%
7776	49 Neutral	¥16.74B	―		―	-22.81%	2.69%
4599	47 Neutral	¥19.82B	―		―	―	8.47%
4894	33 Underperform	¥55.81B	―		―	1242.62%	2.56%

Healios KK Corporate Events

Healios Secures Patent Approval for Universal Donor Cells in Japan

Healios K.K. announced the approval of a patent for its Universal Donor Cells (UDCs) by the Japan Patent Office, marking a significant milestone in the company’s innovation in regenerative medicine. The UDC technology, which reduces immune rejection risks, enhances Healios’ competitive edge globally and positions its UDCs as a potential industry standard, facilitating joint research and licensing agreements worldwide.

The most recent analyst rating on (JP:4593) stock is a Buy with a Yen320.00 price target. To see the full list of analyst forecasts on Healios KK stock, see the JP:4593 Stock Forecast page.

Healios K.K. Secures JPY 7 Billion Subsidy for CDMO Business Expansion

Healios K.K. has been selected for a JPY 7 billion subsidy under Japan’s METI program to support capital investment in regenerative, cell, and gene therapy manufacturing facilities. This funding will enable Healios to expand its CDMO business, enhancing its competitive edge in the global market by integrating advanced technologies and establishing a robust international platform. The initiative aligns with Japan’s industrial policy and aims to strengthen Healios’s position as a leader in regenerative medicine, fostering new partnerships and enhancing shareholder value.

The most recent analyst rating on (JP:4593) stock is a Buy with a Yen320.00 price target. To see the full list of analyst forecasts on Healios KK stock, see the JP:4593 Stock Forecast page.